Alpha-gal Allergy

To begin the course, please login or register by clicking ENROLL. After logging in, you will be able to complete the pretest and view the video/documents. You will have the option to complete the posttest, evaluation and receive credit. Some courses may have an associated cost.

Step Status
Video/Document(s)
Posttest
Evaluation
Starts On: 7/1/2019: 12:00 AM
Ends On: 6/30/2020: 12:00 AM
Session Type: Internet Activity Enduring Material
Credits: 0.5
Description:

Faculty

Brooke I. Polk, MD
Assistant Professor of Pediatrics, Allergy, Immunology and Pulmonary Medicine
Division of Pediatric Allergy, Immunology and Pulmonary Medicine
Disclosures
Financial Relationships: Speaker has nothing to disclose.

Presenters should indicate if speaking off label. This activity originated as a presentation at the CME activity, Clinical Allergy for the Practicing Physician, August 17-18, 2018, which was supported in part by CSL Behring, Lincoln Diagnostics, Inc. and Stallergenes Greer.

Planning Committee

Tiffany Dy, MD, Assistant Professor of Medicine (Course Chair)
Financial Relationships: Speaker has nothing to disclose.
Andrew L. Kau, MD, PhD, Assistant Professor of Medicine (Course Co-Chair)
Financial Relationships: Ownership Investment: Gilead Scineces, Viosera Therapeutics
Jennifer Monroy, MD, Assistant Professor of Medicine
Financial Relationships: Speaker has nothing to disclose
Sandra Odenwald, RN
Financial Relationships: Speaker has nothing to disclose
Jeffrey R. Stokes, MD Professor of Pediatrics
Financial Relationships: Speaker has nothing to disclose

Objectives: The intended result of this activity is increased knowledge/competence, and upon completion of this course, participants should be able to:
  • To appreciate the history, epidemiology, pathophysiology and management of galactose-alpha-1,3-galactose ("alpha-gal") allergy.
  • To be able to expand on the differential of idiopathic anaphylaxis.
Additional Information:
Target Audience: This course is designed for allergists, immunologists, pulmonologists, primary care and family practice physicians, otolaryngologists, pediatricians, internists, dermatologists, nurse practitioners, nurses, physician assistants and all allied health professionals who care for patients with allergic and immunologic illnesses

Publication Date: July 1, 2019
Expiration Date: June 30, 2020

Accreditation Information:
wustlcme
In support of improving patient care, Washington University School of Medicine in St. Louis is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Awarded for this Activity:

Credit Statement:
American Medical Association (AMA Credit)
Washington University School of Medicine in St. Louis designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

References:
  • U Galili, E A Rachmilewitz, A Peleg, I Flechner A unique natural human IgG antibody with anti-alpha-galactosyl specificity. Journal of Experimental Medicine Nov 1984, 160 (5) 1519-1531; DOI: 10.1084/jem.160.5.1519
  • Chung CH et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med. 2008 Mar 13;358(11):1109-17
  • Commins S et al. Delayed anaphylaxis, angioedema, or urticaria after consumption of red meat in patients with IgE antibodies specific for galactose-alpha-1,3-galactose. J Allergy Clin Immunol. 2009 Feb;123(2):426-33.
  • Delayed clinical and ex vivo response to mammalian meat in patients with IgE to galactose-alpha-1,3-galactose. J Allergy Clin Immunol. 2014 Jul; 134(1):108-15.
Disclosure Information: It is the policy of Washington University School of Medicine in St. Louis, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational activities. All planners, faculty and other persons who may influence content of this CME activity have disclosed all relevant financial relationships with commercial interests. All disclosures have been reported and are indicated with their presentations. Any potential conflicts were addressed and resolved.

Presenters are also expected to openly disclose inclusion of discussion of any off-label, experimental, or investigational use of drugs or devices in their presentations.

Presentations are expected to be based on evidence that is accepted within the profession of medicine as adequate justification for their indication in the care of patients. All scientific research should conform to the generally accepted standards of experimental design, data collection and analysis. These presentations are not an endorsement of any commercial interests.

These presentations are the views and experiences of the presenters. The presenters' views do not represent the policy or position of Washington University School of Medicine in St. Louis. Washington University School of Medicine in St. Louis, Continuing Medical Education, is the provider for CME credits.
Categories: Allergy, Pulmonology


Powered By AI 4.5